Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Compulsory licences: necessity or threat?

23 May 2013 Comments

news image

Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?

Most Read

Mystery of coloured water droplets that chase and repel each other solved

19 March 2015 Research

news image

Discovery could herald sprays that hoover up dirt and keep solar panels clean

Simple cooking changes make healthier rice

23 March 2015 Research

news image

Adding oil to water, cooling and reheating rice makes fibre-like resistant starch, reducing calories

Most Commented

Worrying molecule found in bottled water

9 September 2013 Research

news image

Analysis finds a new endocrine disrupting chemical in bottled water

Impatient chemistry

28 February 2014 Last Retort

news image

Is the pressure to publish making chemists cut corners?